FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer
Objective: To investigate the role of forkhead box protein M1 (FOXM1) mRNA expression and its prognostic value in stage pT1 non-muscle-invasive bladder cancer (NMIBC). Patients and Methods; Clinical data and formalin-fixed paraffin-embedded tissues from transurethral resection of the bladder from pa...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2019
|
| In: |
BJU international
Year: 2018, Jahrgang: 123, Heft: 1, Pages: 187-196 |
| ISSN: | 1464-410X |
| DOI: | 10.1111/bju.14525 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1111/bju.14525 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bju.14525 
|
| Verfasserangaben: | Johannes Breyer, Ralph M. Wirtz, Philipp Erben, Sebastien Rinaldetti, Thomas S. Worst, Robert Stoehr, Markus Eckstein, Danijel Sikic, Stefan Denzinger, Maximilian Burger, Arndt Hartmann and Wolfgang Otto |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1671475291 | ||
| 003 | DE-627 | ||
| 005 | 20220816210801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190815r20192018xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bju.14525 |2 doi | |
| 035 | |a (DE-627)1671475291 | ||
| 035 | |a (DE-599)KXP1671475291 | ||
| 035 | |a (OCoLC)1341237939 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Breyer, Johannes |e VerfasserIn |0 (DE-588)1155510593 |0 (DE-627)1017777454 |0 (DE-576)501694145 |4 aut | |
| 245 | 1 | 0 | |a FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer |c Johannes Breyer, Ralph M. Wirtz, Philipp Erben, Sebastien Rinaldetti, Thomas S. Worst, Robert Stoehr, Markus Eckstein, Danijel Sikic, Stefan Denzinger, Maximilian Burger, Arndt Hartmann and Wolfgang Otto |
| 264 | 1 | |c 2019 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published: 18 August 2018 | ||
| 500 | |a Gesehen am 15.08.2019 | ||
| 520 | |a Objective: To investigate the role of forkhead box protein M1 (FOXM1) mRNA expression and its prognostic value in stage pT1 non-muscle-invasive bladder cancer (NMIBC). Patients and Methods; Clinical data and formalin-fixed paraffin-embedded tissues from transurethral resection of the bladder from patients with stage pT1 NMIBC, treated with an organ-preserving approach, were analysed retrospectively. Total RNA was isolated using commercial RNA extraction kits, and mRNA expression of FOXM1, MKI67, KRT20 and KRT5 was measured by single-step quantitative RT-PCR using RNA-specific TaqMan Assays. Statistical analysis was performed using Spearman's Rho, Wilcoxon or Kruskal–Wallis tests, Kaplan–Meier estimates of recurrence-free (RFS), progression-free (PFS) and cancer-specific survival (CSS) and Cox regression analysis. Results: Data from 296 patients (79.4% men, median age 72 years) were available for the final evaluation. Spearman correlation analysis showed that mRNA expression of FOXM1 was significantly correlated with MKI67 (ρ: 0.6530, P < 0.001) and with the luminal subtype, reflected by the positive correlation with KRT20 (ρ: 0.2113, P < 0.001). Furthermore, there was also a strong correlation of FOXM1 expression with adverse clinical and pathological variables, such as concomitant carcinoma in situ (P = 0.05), multifocal tumours (P = 0.005) and World Health Organization 1973 grade 3 disease (P < 0.001). Kaplan–Meier analysis showed overexpression of FOMX1 to be associated with worse PFS (P = 0.028) and worse CSS (P = 0.015). FOXM1 overexpression was also shown to be a predictive risk factor for CSS (hazard ratio 1.61 [1.13–2.34], L-R chi-squared: 7.19, P = 0.007). FOXM1 overexpression identified a subgroup of patients within the luminal subtype with worse RFS (P = 0.017), PFS (P < 0.001) and CSS (P = 0.015). Patients with low FOXM1 expression had better outcomes, irrespective of instillation therapy, whereas patients with high FOXM1 expression benefitted from intravesical chemotherapy with mitomycin C. Conclusion: High FOXM1 expression was associated with adverse clinical and pathological features and worse outcomes, and predicted response to intravesical instillation therapy in patients with stage pT1 NMIBC. | ||
| 534 | |c 2018 | ||
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a FOXM1 | |
| 650 | 4 | |a instillation therapy | |
| 650 | 4 | |a non-muscle-invasive bladder cancer | |
| 650 | 4 | |a pT1 | |
| 700 | 1 | |a Erben, Philipp |d 1973- |e VerfasserIn |0 (DE-588)128501014 |0 (DE-627)373920997 |0 (DE-576)297181661 |4 aut | |
| 700 | 1 | |a Rinaldetti, Sébastien |d 1988- |e VerfasserIn |0 (DE-588)1073669157 |0 (DE-627)829329730 |0 (DE-576)435254952 |4 aut | |
| 700 | 1 | |a Worst, Thomas |d 1985- |e VerfasserIn |0 (DE-588)1028335679 |0 (DE-627)73058500X |0 (DE-576)375827501 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BJU international |d Oxford : Wiley-Blackwell, 1999 |g 123(2019), 1, Seite 187-196 |h Online-Ressource |w (DE-627)320599426 |w (DE-600)2019983-1 |w (DE-576)091140862 |x 1464-410X |7 nnas |a FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer |
| 773 | 1 | 8 | |g volume:123 |g year:2019 |g number:1 |g pages:187-196 |g extent:10 |a FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1111/bju.14525 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bju.14525 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190815 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1028335679 |a Worst, Thomas |m 1028335679:Worst, Thomas |d 60000 |d 63100 |e 60000PW1028335679 |e 63100PW1028335679 |k 0/60000/ |k 1/60000/63100/ |p 5 | ||
| 998 | |g 1073669157 |a Rinaldetti, Sébastien |m 1073669157:Rinaldetti, Sébastien |d 60000 |d 61200 |e 60000PR1073669157 |e 61200PR1073669157 |k 0/60000/ |k 1/60000/61200/ |p 4 | ||
| 998 | |g 128501014 |a Erben, Philipp |m 128501014:Erben, Philipp |d 60000 |d 63100 |e 60000PE128501014 |e 63100PE128501014 |k 0/60000/ |k 1/60000/63100/ |p 3 | ||
| 999 | |a KXP-PPN1671475291 |e 3507235714 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"10 S."}],"id":{"doi":["10.1111/bju.14525"],"eki":["1671475291"]},"relHost":[{"pubHistory":["83.1999 -"],"part":{"year":"2019","text":"123(2019), 1, Seite 187-196","volume":"123","issue":"1","pages":"187-196","extent":"10"},"language":["eng"],"title":[{"subtitle":"the journal of the British Association of Urological Surgeons, the European Society of Paediatric Urology and the Societé Internationale d'Urologie","title":"BJU international","title_sort":"BJU international"}],"origin":[{"dateIssuedKey":"1999","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell","dateIssuedDisp":"1999-","publisherPlace":"Oxford ; Oxford ; Oxford [u.a.]"}],"recId":"320599426","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 14.03.25"],"disp":"FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancerBJU international","id":{"doi":["10.1111/(ISSN)1464-410X"],"issn":["1464-410X"],"zdb":["2019983-1"],"eki":["320599426"]},"physDesc":[{"extent":"Online-Ressource"}]}],"note":["First published: 18 August 2018","Gesehen am 15.08.2019"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1671475291","origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"2019"}],"person":[{"family":"Breyer","display":"Breyer, Johannes","given":"Johannes","role":"aut"},{"family":"Erben","display":"Erben, Philipp","role":"aut","given":"Philipp"},{"display":"Rinaldetti, Sébastien","given":"Sébastien","role":"aut","family":"Rinaldetti"},{"family":"Worst","display":"Worst, Thomas","given":"Thomas","role":"aut"}],"name":{"displayForm":["Johannes Breyer, Ralph M. Wirtz, Philipp Erben, Sebastien Rinaldetti, Thomas S. Worst, Robert Stoehr, Markus Eckstein, Danijel Sikic, Stefan Denzinger, Maximilian Burger, Arndt Hartmann and Wolfgang Otto"]},"title":[{"title_sort":"FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer","title":"FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer"}],"language":["eng"]} | ||
| SRT | |a BREYERJOHAFOXM1OVERE2019 | ||